Cost/benefit aspects on thromboprophylaxis.
Several studies have shown thromboprophylaxis of any kind to be more cost-effective than no prophylaxis or general diagnostic surveillance and selective treatment. Little has been written on low molecular weight heparins from the cost-effectiveness point of view. This preliminary study shows low molecular weight heparin to be more cost-effective than standard low-dose heparin in most situations of prophylaxis.
Department of Surgery, Lund University, Malmö General Hospital, Sweden.
D
D
Bergqvist
T
T
Mätzsch
D000005:Abdomen / Q000601:surgery; D003362:Cost-Benefit Analysis; D006493:Heparin / Q000191:economics / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000191:economics / Q000627:therapeutic use; D006622:Hip Prosthesis; D006801:Humans; D011182:Postoperative Care / Q000191:economics*; D011183:Postoperative Complications / Q000191:economics / Q000517:prevention & control*; D011446:Prospective Studies; D012306:Risk; D013548:Sweden; D013923:Thromboembolism / Q000191:economics / Q000517:prevention & control*
D006495:Heparin, Low-Molecular-Weight; D006493:Heparin